Evidence map›Paper›PMID 40026917›Full record

ReviewCureus2025

Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities.

Yozahandy A Abarca, Renee Scott-Emuakpor, Jhanavi Tirth, Oksana Moroz, George Pandarakalam Thomas, Dana Yateem, Rebecca Golbari, Ninigail Aphia, Yuliya Lysak, Niketa Narasimhan and 1 more

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yozahandy A AbarcaInternal Medicine, School of Medicine and Health Sciences, Technological Institute of Monterrey, Monterrey, MEX.
Renee Scott-EmuakporDermatology, University of Miami Miller School of Medicine, Miami, USA.
Jhanavi TirthCollege of Medicine, Smt. Nathiba Hargovandas Lakhmichand (NHL) Municipal Medical College, Ahmedabad, IND.
Oksana MorozDermatology, Dr. Andrew Simone - Walk-in Dermatology Clinic, Toronto, CAN.
George Pandarakalam ThomasInternal Medicine, Dorset County Hospital, Dorchester, GBR.
Dana YateemDermatology, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, GBR.
Rebecca GolbariDermatology, Technion American Medical School, Los Angeles, USA.
Ninigail AphiaMedicine, Thoothukudi Medical College, Thoothukudi, IND.
Yuliya LysakMedicine, St. George's University, St. George's, GRD.
Niketa NarasimhanBiology, Miami University, Oxford, USA.
Humza F SiddiquiInternal Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alopecia areata (AA) is an autoimmune condition that presents with non-scarring hair loss affecting multiple patients worldwide during their lifetime. It ranges from well-defined patchy to diffuse total hair loss, impacting all hair-bearing areas of the body. AA most commonly predominantly manifests on the scalp. The pathophysiology of AA is complex and multi-faceted. The findings of our review article were consistent with the recent literature, delineating autoimmunity, genetic susceptibility, and environmental aspects to be the contributing factors. One of the main causes of AA is believed to be the disruption in the immune privilege of the hair follicles. Multiple genetic loci involved in hair follicle maturation and immune process have been linked to the development of AA as evidenced by several studies. It has been postulated that psychological stressors, smoking, alcohol consumption, sleep disturbances, gut microbiota, and drugs play a role in the pathogenesis of AA by exacerbating the immune response against the hair follicles. AA is a clinically diagnosed disorder. Topical, intra-lesional, and oral corticosteroids, topical and oral minoxidil, cyclosporine, and other immune therapy drugs are widely accepted first-line treatment options, although incomplete remission and relapses are common. Recently JAK-2 inhibitors and mesenchymal stem cell exosomes have shown promising results, potentially treating severe and refractory hair loss. AA has a bidirectional relationship with psychological symptoms as it can lead to social anxiety and depression, which in turn can aggravate hair loss. Hence, it is crucial to implement a holistic approach to managing AA including topical and systemic therapies, psychological counseling, and lifestyle modifications. It is imperative to fully declinate the pathophysiological mechanisms of the disease and formulate therapies in future research to help clinicians and dermatologists devise definitive guidelines to treat the condition for long-term remission.

Indexed as

alopecia areatahair follicleshair lossimmune privilege lossimmunotherapyintralesional corticosteroidjak inhibitormesenchymal stem cell therapyminoxidil

Identifiers

PMID40026917
PMCPMC11872173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.